噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床观察

Clinical observation for tiotropium bromide in the treatment of stable chronic obstructive pulmonary disease

目的观察噻托溴铵粉吸入剂治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效和不良反应。方法 88例Ⅱ-Ⅲ级COPD稳定期患者,随机分为噻托溴铵组(n=42)和对照组(n=46)。噻托溴铵组在常规治疗基础上一日1次吸入噻托溴铵粉吸入剂(每次18μg),对照组仅接受常规治疗,疗程均为6月。结果与对照组相比,噻托溴铵治疗组病例急性加重次数明显减少(P<0.05),症状评分、生活质量评分和运动耐力变化等均有明显改善(P<0.05)。药物不良反应较少,主要为尿潴留和口干。结论一日1次吸入噻托溴铵粉吸入剂可明显减少COPD患者急性加重次数,改善患者的症状,提高生活质量和运动耐力,且药物不良反应少。

Objective To observe the efficacy and adverse reactions of inhaled tiotropium bromide for patients with stable chronic obstructive pulmonary disease （COPD）. Methods Eighty-eight COPD cases with a stable phase of Ⅱ to Ⅲ were randomly devided into two groups. The patients in tiotropium bromide group were inhaled tiotropium bromide based on conventional treatment. The patients in control group were administered with conventional treatment. The courses of treatment in both groups were six months. Results Compared with the control group, the times of acute exacerbation of patients in tiotropium bromide group reduced remarkably （P〈0.05）. The clinic symptom grade, score of quality for life and six-minutes walking distance of the tiotropium bromide group were improved significantly. The major adverse reactions were dry mouth and uroschesis. Conclusion Tiotropium bromide （once-daily 18 μg inhaled） can significantly reduce the times of acute exacerbation and improve symptoms, exercise tolerance and quality with life of the COPD patients without major adverse reactions.